Maternal and foetal outcome following Hodgkin's disease in pregnancy.
The peak incidence of Hodgkin's disease occurs during the reproductive age, and its association with pregnancy is at a rate of between 1:1,000-1:6,000. We studied the effects of Hodgkin's Disease on the course and survival of 48 women who had Hodgkin's Disease and who were pregnant, and compared their outcome with non-pregnant matched women who were of similar stage of disease, age at diagnosis, and calenderic year of treatment. Twenty-year survival of pregnant women with Hodgkin's Disease was not different from that of their matched controls. Pregnant women with Hodgkin's Disease had similar distribution of stages to the controls.
Lishner
M
M
Department of Pediatrics, Hospital for Sick Children, Toronto, Canada.
Zemlickis
D
D
Degendorfer
P
P
Panzarella
T
T
Sutcliffe
S B
SB
Koren
G
G
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001724:Birth Weight; D016022:Case-Control Studies; D002585:Cesarean Section; D003131:Combined Modality Therapy; D036861:Delivery, Obstetric; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006689:Hodgkin Disease / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy; D006801:Humans; D006849:Hydrocephalus; D007231:Infant, Newborn; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000503:physiopathology*; D011256:Pregnancy Outcome; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone